Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression

In a pragmatic trial involving older persons with treatment-resistant depression, augmentation of existing antidepressants with aripiprazole was better than augmentation with bupropion or a switch to bupropion.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-03, Vol.388 (12), p.1067-1079
Hauptverfasser:	Lenze, Eric J., Mulsant, Benoit H., Roose, Steven P., Lavretsky, Helen, Reynolds, Charles F., Blumberger, Daniel M., Brown, Patrick J., Cristancho, Pilar, Flint, Alastair J., Gebara, Marie A., Gettinger, Torie R., Lenard, Emily, Miller, J. Philip, Nicol, Ginger E., Oughli, Hanadi A., Pham, Vy T., Rollman, Bruce L., Yang, Lei, Karp, Jordan F.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aging Aging General Antidepressants Antidepressive Agents - adverse effects Antidepressive Agents - therapeutic use Aripiprazole Aripiprazole - adverse effects Aripiprazole - therapeutic use Bupropion Bupropion - adverse effects Bupropion - therapeutic use Clinical Medicine Clinical Medicine General Depression Design Drug dosages Drug Therapy, Combination Geriatric psychiatry Geriatrics Humans Lithium Lithium Compounds - adverse effects Lithium Compounds - therapeutic use Mental depression Neurology Neurosurgery Neurosurgery General Nortriptyline - adverse effects Nortriptyline - therapeutic use Older people Patient-centered care Patients Primary care Psychiatry Remission Remission (Medicine) Treatment resistance Treatment Switching Well being
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!